AbbVie Inc.
0QCV.IL
Get informed when a big investor buys or sells
+ FollowMarket Cap$486.84B
Close$
Share Statistics
| Market cap | $486.84 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $6.83 (2.48%) |
| Earnings per Share | $- |
| Beta | 0.41 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$3.61
Average shareholder expectationRevenue Estimate
$16.80 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$3.83
Average shareholder expectationRevenue Estimate
$17.33 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AbbVie Inc.
57,000 employees
CEO: Robert A. Michael AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to trea...